Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus
  • Aires thérapeutiques
  • Articles
  • Éducation
  • Divers
Campus
  • Aires thérapeutiques
  • Articles
  • Éducation
  • Divers

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques
The RESTORE-G Real World Evidence Study

The RESTORE-G Real World Evidence Study

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

Explorer
The observational ORION study

The observational ORION study

Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.

Explorer
Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?<sup>1</sup>

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Explorer
Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Explorer
Le pouvoir de réduire le chaos lié au VRS<sup>1-4</sup>

Le pouvoir de réduire le chaos lié au VRS

Explorer
When to Initiate Basal Insulin?

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Explorer
Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Explorer
Cardiovascular diseases (CVDs) are the leading cause of death globally<sup>1</sup>

Cardiovascular diseases (CVDs) are the leading cause of death globally

Explorer
Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Explorer
Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Explorer
How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Explorer
Signs and symptoms of aTTP

Signs and symptoms of aTTP

Know the signs and symptoms of acquired TTP (aTTP).

Explorer